Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Life Molecular Imaging Announces Start of Phase 3 Study with [18F]Florbetaben in Cardiac Amyloid Light Chain (AL) Amyloidosis


News Image

[18F]florbetaben PET imaging of patients with suspected cardiac amyloidosis has the potential to become an important tool to simplify and shorten the time to diagnosis, providing earlier and appropriate access to therapy and improved monitoring of such interventions

Life Molecular Imaging (LMI) announces today that the first patient has been imaged with [18F]florbetaben in the CArdiag Phase 3 clinical study. This is an open-label, multi-center, non-randomized pivotal Phase 3 study to evaluate the diagnostic efficacy of [18F]florbetaben Positron Emission Tomography (PET) imaging to diagnose cardiac AL amyloidosis in patients with suspected cardiac amyloidosis.

The CArdiag Phase 3 clinical program will be performed in Germany, Spain, UK and US – and will enroll approximately 200 patients globally. The primary objective is to determine the sensitivity and specificity of the visual assessment of [18F]florbetaben PET images for the diagnosis of cardiac AL amyloidosis compared to standard of care clinical diagnosis.

[18F]florbetaben PET is validated and approved to detect neuritic beta amyloid plaques in the brain and available via a global supply network marketed as Neuraceq®. Initial clinical data showed that amyloid deposits of other origin in the heart, such as AL amyloid and transthyretin (TTR) amyloid, can also be detected. Based on these data, the European Commission and the U.S. Food and Drug Administration granted orphan drug designation to [18F]florbetaben in 2020 as a diagnostic tool for AL amyloidosis. The detection of amyloid deposits in the heart will be further investigated and validated in the current Phase 3 trial. Exploratory analyses will evaluate the possibility for a differential diagnosis between the two main types (AL and ATTR) of cardiac amyloidosis by [18F]florbetaben PET.

“Expanding the indication for our amyloid PET tracer from detecting ß-amyloid deposits in the brain to detecting amyloid deposits in the heart in patients with cardiac amyloidosis will allow us to support an earlier diagnosis of this rare and life-threatening disease”, said Dr. Ludger Dinkelborg, CEO of Life Molecular Imaging. “We are proud to announce the start of this Phase 3 study, which marks another milestone on our vision to reduce the burden of disease by improving early diagnosis and characterization of chronic and life-threatening diseases.”

“Cardiac AL amyloidosis is a progressive and life-threatening disease, and its diagnosis and treatment are challenging”, said Dr. Andrew Stephens, MD, PhD, CMO of Life Molecular Imaging. “[18F]florbetaben PET imaging of patients with suspected cardiac amyloidosis has the potential to become an important tool to simplify and shorten the time to diagnosis, providing earlier and appropriate access to therapy and improved monitoring of such interventions.”

Further details of the CArdiag Phase 3 study design are available on clinicaltrials.gov (NCT05184088).

About [18F]florbetaben

[18F]florbetaben is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain. [18F]florbetaben has been approved by the FDA and EMA for routine clinical use, and has local regulatory approval in other countries such as Japan and Korea. It binds to beta sheet structure of amyloid proteins. [18F]florbetaben is marketed as Neuraceq® to estimate the neuritic beta amyloid plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. [18F]florbetaben is currently under investigation as a targeted radiopharmaceutical for the detection of amyloid deposits in the heart and other organs of patients with cardiac and systemic amyloidosis of AL and ATTR type.

Most Common Adverse Reactions

In clinical trials including demented and non-demented subjects, the most frequently observed adverse drug reactions in 872 subjects with 1090 Florbetaben (18F) administrations were injection/application site erythema (1.7%), injection site irritation (1.1%), and injection site pain (3.4%).

About Life Molecular Imaging (LMI)

Life Molecular Imaging (LMI, formerly Piramal Imaging) was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. It is now part of the Alliance Medical Group (a member of the Life Healthcare Group) offering an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. By developing novel PET tracers for molecular imaging, LMI is focusing on a key field of modern medicine. The organization strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. Please visit https://life-mi.com.

About Life Healthcare Group

Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 38 years’ experience in the South African private healthcare sector, and currently operates 66 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, and wellness, occupational health, primary health and emergency medical services. The Group owns Alliance Medical Group, the leading independent provider of medical imaging services (MRI, CT and PET scans) within Europe, operating internationally across 10 countries. Life Molecular Imaging, a division of Alliance is an integrated pharmaceutical business that includes research and development laboratories, access to a network of cyclotrons and radio-pharmacies and imaging facilities, with Life Radiopharma being Alliance’s distributor of radiopharmaceuticals to diagnose many types of diseases. Visit https://www.lifehealthcare.co.za/

Media Contact:

Dr Iris Hardewig

i.hardewig[at]life-mi.com

Share article on social media or email:

CytoVeris Publishes Preclinical Study Showing Potential of its TumorMAP System for Cancer Detection


News Image

CytoVeris Inc., a medical device company developing AI-powered cancer imaging technologies to enable more precise surgical decision-making and improve patient outcomes, today announced the publication of preclinical data showing the potential of its TumorMAPTM system to detect cancer. The system is based on a proprietary Multi-Spectral Tissue Auto-Fluorescence Imaging (MS-TAFI) technology that analyzes the “optical fingerprint” of tissue and deciphers its intrinsic biomolecular and morphological characteristics without the use of dyes or imaging agents. The study is published in the peer-reviewed journal Archives of Pathology and Laboratory Medicine. This technology has the potential to evaluate resection margins intraoperatively during surgical procedures.

“It is remarkable to witness the CytoVeris TumorMAP system accurately detecting cancer in near-real time in a label-free manner,” said Malini Harigopal, MD, Director of Immunohistochemistry Laboratory and Breast Pathology Fellowship Director at Yale School of Medicine and corresponding author of the paper. “We are excited to be part of this study and its promising preliminary results. Presently, pathologists spend considerable time determining the distance of the invasive or in situ carcinoma from the true margin to better assist surgeons in re-excising close or positive margins in breast cancers. This technology has the capability to check margin status in vivo right in the operation suite and may impact margin re-excision rates in the future more accurately. This study, though preliminary, is highly innovative with far-reaching applications for other organ sites where margin evaluation is critical.”

Minghao Zhong, MD, PhD, Associate Professor of Pathology at Yale School of Medicine and co-author of the paper said, “We are thrilled to contribute to the preclinical validation of the CytoVeris device. In addition to its intended application in surgery, this device shows its utility for use in processing and prioritizing specimens during frozen section and in the pathology grossing room.”

Approximately 300,000 women in the United States are diagnosed with breast cancer each year, and a significant number of these patients undergo breast-conserving surgery (BCS) as part of the standard of care for the treatment of the disease. Repeated surgery is necessary for 20 to 35 percent of breast conservation surgeries due to the absence of any adjunctive, accurate, and objective tool in the surgeon’s hand that can be used for real-time margin assessment and to achieve the desired balance of oncologic and cosmetic outcomes. This innovative application of AI-powered imaging assists surgeons in accurately identifying margin status intraoperatively.

“Our innovative platform technology marries AI with advanced imaging and has the unique flexibility to be applied for tissue identification,” said Rishikesh Pandey, Ph.D., Chief Scientist of CytoVeris. “We are very passionate about our platform technology, committed to improving outcomes of oncologic patients, and excited to have our first preclinical study published in this prestigious journal.”

CytoVeris was founded on the vision that, by leveraging advanced optical imaging and artificial intelligence, surgeons will have the ability to discern a specific tissue type where it matters most – in the operating room,” said Dr. Alan D. Kersey, President and CEO of CytoVeris. “This study demonstrates the potential for our technology to improve the precision of breast cancer resection, but we won’t stop there. We are committed to addressing the needs of other large and growing oncologic markets as well, including bladder and prostate cancers.”

Read more at:

https://meridian.allenpress.com/aplm/article/doi/10.5858/arpa.2022-0228-OA/490548/AI-Powered-Biomolecular-Specific-and-Label-Free

About CytoVeris:

With a passion for science and compassion for cancer patients, CytoVeris is leveraging the convergence of powerful multispectral imaging technology, knowledge of intrinsic biochemical attributes of tissue, and explainable artificial intelligence to bring new capabilities into the hands of surgeons to improve resection quality. CytoVeris proprietary Multi2-Spectral Auto-Fluorescence Imaging (MS-AFI) system, will assist cancer surgeons to discern target tissue in real-time during surgery and as a result will increase the probability of successful cancer surgery and outcomes in open, minimally invasive surgery and robotically assisted procedures. To learn more, visit http://www.cytoveris.com.

Share article on social media or email:

Adaptive Clinical Systems Joins Veeva’s Technology Partner Community As A Certified Data Interoperability Partner for Veeva Vault


Adaptive Clinical Bus Solves Clinical Research Interoperability Challenges

Adaptive Clinical Bus Solves Clinical Research Interoperability Challenges

“As the clinical research industry trends towards more complex studies, even small to mid-size sponsors find themselves in a multi-CRO environment with disparate systems in need of interoperability,” said Sina Adibi, CEO and President, Adaptive Clinical Systems.

Adaptive Clinical Systems is pleased to announce that it has been selected to join the Veeva Vault partner community as a Certified Technology Partner for clinical research data interoperability.

“As the clinical research industry trends towards more complex studies, even small to mid-size sponsors find themselves in a multi-CRO environment with disparate systems in need of interoperability,” said Sina Adibi, CEO and President, Adaptive Clinical Systems.

This technology partnership will enable existing and future Veeva Vault customers to easily collect and aggregate critical operational data from disparate sources into and out of the Veeva Vault platform including such areas as CTMS, Safety and CDB. As a result of this partnership, Adaptive Clinical will streamline Veeva Vault implementations that require interoperability to improve performance at a fraction of the cost of a custom solution. Furthermore, sponsors will be able to integrate and leverage this investment towards real-time patient monitoring and clinical study monitoring using the Adaptive eClinical Bus and Adaptive DataVIEW reporting and visualization solution. Veeva product capabilities are further augmented through universal compatibility and interoperability with the Adaptive Clinical ecosystem. With a full library of third-party interconnects, Veeva clients can exchange data with any tool to enable holistic data management.

Adaptive Clinical Systems, a global life sciences technology company, provides the leading data integration platform for clinical research. With the Adaptive eClinical Bus® and Adaptive DataVIEW®, see how your clinical trial data is transformed with data in motion. Adaptive Clinical’s solutions enable data streams across all study partners and eClinical eSources. Whether your challenge is data visualization, API integrations or data integration, our solutions help remove data islands and silos. We make your data actionable faster. For more information, please see Adaptive Clinical Systems website: http://www.adaptive-clinical.com.

Share article on social media or email:

Meller Optics Introduces Sapphire Medical Optics that are Impervious to Harsh Chemicals, Blood, and Medications


News Image

Meller Sapphire Medical Optics are optically clear and manufactured to OEM specifications in sizes from 0.25” to 10” dia. in round or square, concave or convex, and flat or stepped configurations.

Ideally suited for instruments that are in contact with the skin and cleaned frequently, sapphire is impervious to chlorine and fluorine gas, and can transmit from the UV to 4.7 microns.

Meller Optics, Inc. introduces custom sapphire lenses, windows, and prisms designed for use in medical lasers, endoscopes, oximeters, and other instruments.

Meller Sapphire Medical Optics are impervious to harsh chemicals, blood, and medications and are extremely durable and available as lenses, windows, and prisms. Ideally suited for instruments that are in frequent contact with the skin and cleaned frequently, sapphire is impervious to chlorine and fluorine gas, and can transmit from the UV to 4.7 microns.

Featuring Mohs 9 hardness which is second only to diamond, Meller Sapphire Medical Optics are optically clear and manufactured to OEM specifications in sizes from 0.25” to 10” dia. in round or square, concave or convex, and flat or stepped configurations. Sapphire windows transmit up to 85% uncoated and can be coated to transmit > 99%, depending upon thickness.

Meller Sapphire Medical Optics are priced according to material, configuration, and quantity. Quotations are provided upon request.

For more information contact:

Meller Optics, Inc.

Steve Lydon, Marketing

120 Corliss St. / P.O. Box 6001

Providence, RI 02940

(800) 821-0180 FAX (401) 331-0519    

e-mail: steve@melleroptics.com

http://www.melleroptics.com

Share article on social media or email:

Flagship Biosciences and Genomenon Partner to Advance Precision Medicine Development


Flagship Biosciences’ biomarker data services are critical to informing precision medicine decisions, and together with Genomenon’s disease-specific genomic datasets powered by the Mastermind knowledgebase, the two companies provide unique insight to improve the clinical trial process.

Flagship Biosciences, a leader in spatial biology and biomarker analytics services, today announced a strategic partnership with Genomenon® that aims to transform the drug development paradigm with accelerated biomarker discovery and companion diagnostics development solutions.

Flagship Biosciences has long been recognized for its innovative spatial biology services, fueled by AI image analysis technology that improves the accuracy of tissue-based pathology. With its recent acquisition of Interpace Pharma Solutions, Flagship has expanded its portfolio to include proven cytogenetic, molecular pathology and genomic profiling solutions. By partnering with Genomenon, the company will further enrich its genomic profiling capabilities with the unparalleled breadth of published clinical genomic evidence only available in the Genomenon Mastermind™ knowledgebase.

Through its AI-driven genomics platform, Genomenon delivers disease-specific genomic datasets that identify the most comprehensive set of causative variants for a specific disease. These troves of rich genomic information—known as variant landscapes—will complement Flagship Biosciences’ work by accelerating its assay development, validation, and deployment services that support precision medicine drug trials, biomarker discovery, and companion diagnostic development. As a result, this partnership will further enhance new genomic profiling services for biomarker characterization and improved patient stratification for clinical trials and treatment selection.

“This partnership marks an important milestone for our company,” said Flagship Biosciences CEO Trevor Johnson. “By leveraging Genomenon’s cutting-edge technology and expertise, we will be able to deliver genomic profiling services that are even more precise, providing unparalleled insights into biomarker characterization and optimal patient stratification for clinical trials and treatment selection.”

“Flagship Biosciences’ biomarker data services are critical to informing precision medicine decisions, and together with Genomenon’s disease-specific genomic datasets powered by the Mastermind knowledgebase, the two companies provide unique insight to improve the clinical trial process,” said Mike Klein, Genomenon CEO. “Through this partnership, Genomenon will enable the Flagship scientific team to provide their customers with extensive, previously unidentified variant information—giving patients quicker access to life-saving treatments.”

About Flagship Biosciences

Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success. For more information, please visit flagshipbio.com and follow us on Twitter and LinkedIn.

About Genomenon

Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.

Learn more about Genomenon at genomenon.com and follow them on LinkedIn and Twitter.

Share article on social media or email:



Alba Tull Makes $500,000 Gift to the Rett Syndrome Research Trust


RSRT continues to set and drive Rett syndrome research, and this donation is a reflection of my confidence in their singular mission to cure Rett. As an ardent supporter of women in science, I am thrilled to be able to direct this donation to support Dr. Katabi’s innovative work.

Alba Tull has made a generous donation of $500,000 to the Rett Syndrome Research Trust (RSRT) for a clinical study to determine the ability of the Emerald biosensor to accurately measure Rett syndrome symptoms, a key factor necessary for assessing the efficacy of drugs and genetic medicines.

The Emerald — a device developed by Dina Katabi, PhD, co-founder of Emerald Innovations and distinguished professor at MIT — is a freestanding, touchless biosensor that uses the faint wireless signals bouncing around a room to measure physiological information, including breathing, sleep, and movement, all of which are negatively affected in Rett syndrome. The goal of the study is to show that Emerald can accurately measure Rett symptoms, moving it one step closer to becoming a new objective method to assess the efficacy of potential therapeutics in clinical trials and to manage patient symptoms in a clinical care setting. The Emerald sensor has been used in drug development in Alzheimer’s and Parkinson’s; this generous gift allows for testing its efficacy in Rett syndrome.

“RSRT continues to set and drive Rett syndrome research, and this donation is a reflection of my confidence in their singular mission to cure Rett,” said Tull. “As an ardent supporter of women in science, I am thrilled to be able to direct this donation to support Dr. Katabi’s innovative work while advancing the ability to effectively test medicines for Rett syndrome.”

Biopharmaceutical companies engaged with RSRT are highly motivated to develop objective symptom assessment tools, and are collaborating with RSRT and optimistically awaiting results. RSRT funded a pilot study with Emerald in Rett syndrome that generated encouraging results, suggesting that Emerald technology is feasible for Rett syndrome, and that the key symptoms of breathing and sleep disruptions can be reliably assessed and quantified. This next study is anticipated to provide critical data to show that Emerald’s measurements of key Rett symptoms match the current gold standards, though the sensor operates remotely without body contact.

“With two approved gene replacement clinical trials for Rett, Alba’s generous gift comes at a transformational moment,” said RSRT CEO Monica Coenraads. “Her support of the Emerald validation study accelerates our agenda to revolutionize the way clinical trials are designed for Rett. She is a passionate supporter of our cause and has my deep gratitude and admiration.”

Inspired by a friend’s young daughter who was diagnosed with Rett syndrome, Tull joined RSRT’s Board of Trustees in 2016, where her leadership, vision, and support have been invaluable.

“My friend Stephanie Bohn’s daughter, Sadie, was born in 2014. When Stephanie told me Sadie had been diagnosed with Rett syndrome, I was inspired to learn more about the disorder,” Tull shared. “The more I learned, the more I realized how devastating Rett is and how many families are impacted by this life-changing disease. Through Sadie, I’ve learned about the promising research potential for Rett. RSRT has made amazing progress so far and I am confident that RSRT has the ability to truly change lives.”

As chair of the Tull Family Foundation, Ms. Tull is a deeply committed and thoughtful philanthropist with interests in life sciences, education, the safety of children, and other areas. She is also the founder of First Light Capital Group, an investment firm focused on developing and supporting female entrepreneurs predominately in the technology and pharmaceutical industries. In addition to serving on the RSRT board, she is a trustee of the Children’s Hospital of Pittsburgh Foundation, the Pittsburgh’s Carnegie Science Center, the Board of Visitors for the University of Pittsburgh School of Medicine, and The Jackie Robinson Foundation. She is also an acclaimed photographer whose subjects have included numerous celebrities. Her images have been featured in Vanity Fair, Rolling Stone, and other national publications.

Rett syndrome, which afflicts 350,000 people worldwide, is caused by random mutations on the MECP2 gene located on the X chromosome. The disease primarily affects girls and takes effect in toddler-hood following a normal infancy. As Rett progresses children regress and lose acquired skills such as walking, talking, and control of their hands. Scoliosis, extreme anxiety, tremors, seizures, hyperventilation, and digestive problems are common. Most individuals with Rett live into adulthood, requiring round-the-clock care.

ABOUT THE RETT SYNDROME RESEARCH TRUST

RSRT is a nonprofit organization with a highly personal and urgent mission: achieving a cure for Rett syndrome and related disorders caused by defects in the MECP2 gene. Since its founding in 2008, RSRT has awarded $66 million, more than any other Rett organization in the world, to leading scientists pursuing targeted research on Rett. RSRT funds and spearheads global scientific and clinical activities advancing the most promising curative approaches. To date, every biopharmaceutical company pursuing a cure for Rett syndrome is doing so because they leveraged discoveries and resources incubated with RSRT funding. To learn more, please visit http://www.reverserett.org.

Share article on social media or email:

HighWire launches online platform for The British Psychological Society


HighWire Press, a global provider of publishing solutions to the scholarly community, has launched a new website for The British Psychological Society, BPS Explore. The website is hosted on HighWire’s Scolaris platform, backed by access and identity management using Sigma.

The platform also features Single Sign-On (SSO) integration with the BPS website giving its members a seamless journey between scholarly content and its website. Scolaris’s eCommerce functionality has also been configured to give BPS members exclusive discounts, based on which type of membership they have.

BPS is taking advantage of Scolaris’s native capacity to manage multiple content types on the same site. For BPS this consists of its member network periodicals, monographs, reports, guidelines, and test reviews, all on the same search interface. HighWire worked closely with BPS to define the requirements of how the site should look and function through a detailed and collaborative discovery process.

For more than 120 years, The British Psychological Society has championed psychology, psychologists, and the wider psychological professions, supporting their 65,000 members with tools and resources through every stage of their careers.

HighWire’s Scolaris is a next-generation multi-content hosting platform that supports multi-format content, including books, journals, blogs, news, videos, data visualization, and granular content elements. Scolaris includes a full range of tools to support the publishing lifecycle: content ingestion, browsing and embargo support, publication, alerts, taxonomic support, discovery, access control, eCommerce, and analytics.

HighWire’s Sigma provides seamless access for readers and centralized control for administrators. For administrators, it helps keep control of their content without compromising accessibility, enabling fast and easy access to content for users and maximizing value for publishers with a centralized, flexible, and open service for authentication, licensing, and reporting. Readers and researchers benefit from frictionless, single-sign-on access across sites.

“We are delighted to partner with the British Psychological Society,” said Tony Alves, SVP of Product Management at HighWire Press. “With HighWire’s Hosting and Identity solutions, we will support BPS in providing content to their members in a complex and secure way – as well as helping them monetize that content with the public via eCommerce. We look forward to having a long and productive partnership with the BPS.”

“We are excited to partner with HighWire in this key moment of our digitization strategy. Our research resources are at the heart of what we do, and with this move to a fresh, modern platform we will be able to extend our reach and user engagement significantly.” said Debra Malpass, Director of Knowledge & Insight at The British Psychological Society.

###

About HighWire Press

HighWire Press is a leading provider of digital publishing tools and platform solutions, across all aspects of the publishing lifecycle, including content management and hosting, e-commerce, access and identity management, manuscript submission and tracking, and analytics.

Since our inception at Stanford University in the early days of the web, HighWire has remained an innovative leader, focused on the creation, production, and sharing of knowledge. We are now powered by MPS Limited, a global partner to the world’s leading publishers of scholarly and eLearning content and corporates. This combination of deep domain expertise makes HighWire the technology partner of choice for global commercial, society, and academic publishers.

For more information, please visit  highwirepress.com.

About BPS

The British Psychological Society is the leading learned society and professional body in the UK for psychologists. Founded in 1901, the Society received its Royal Charter in 1965 and has a membership of more than 65,000. As the second-largest psychological society worldwide, we have an international reputation for advancing the science and practice of psychology.

To find more information about the Society and how our members can help you and your organization, please visit our website at http://www.bps.org.uk.

Share article on social media or email:

Apollo Awarded Clinical Workflow Solution Agreement with Premier, Inc.


a unique solution as the primary clinical system for both orders- and encounters-based imaging workflows for 45 specialty-specific departments across the healthcare enterprise

“As the Apollo Repository for Clinical Content, arcc, supports health systems to organize and access medical imaging across numerous departments, provides efficient workflows that drive effective care, and converges viewing into a single pane of glass.”

Apollo, a leading provider of enterprise imaging and clinical multimedia management solutions, has been awarded a national group purchasing agreement for clinical workflows with Premier, Inc. Effective December 1, 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Apollo’s enterprise imaging and clinical workflows solution, arcc®.

“We are excited to be awarded this agreement for our arcc solution,” said Mark Newburger, Apollo President and CEO. “As the Apollo Repository for Clinical Content, arcc, supports health systems to organize and access medical imaging across numerous departments, provides efficient workflows that drive effective care, and converges viewing into a single pane of glass.”

Apollo brings a unique solution as the primary clinical system for both orders- and encounters-based imaging workflows for 45 specialty-specific departments across the healthcare enterprise. Apollo arcc provides specialty-specific workflows for the easy acquisition and access of patient clinical media and data collected by healthcare providers while protecting patient privacy. It is a comprehensive solution with a foundation designed specifically for enterprise imaging use.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 225,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.

If you are a Premier member, email Apollo at sales@apolloei.com to learn more about the contracting process.

About Apollo

Apollo is a healthcare IT company with a reputation for delivering quality Enterprise Imaging solutions that address both clinical multimedia workflow management needs and vendor neutral storage requirements. Apollo’s Enterprise Imaging solution, arcc, provides a holistic longitudinal view of all patient data and focuses on clinical workflows, interoperability, and connectivity so that every department throughout the entire enterprise can securely acquire, view, manage, store, and access all clinical content. Integrating arcc to the electronic health record (EHR) provides clinicians a single view of the longitudinal patient record to achieve the goal of: ONE Patient, ONE click, EVERY ‘ology. Used successfully in hospitals across the United States and Canada for 30 years. Visit https://www.apolloei.com/ to learn more.

# # #

Share article on social media or email:

Meridian Knowledge Solutions Makes List for Best LMS for Healthcare, Medical & Telemedicine in 2023


“The team continues to provide an LMS that can adapt to current and projected industry needs while simultaneously upskilling professionals.”

Meridian Knowledge Solutions was honored to be featured on eLearning Industry’s list for Best LMS for Healthcare, Medical & Telemedicine in 2023.

With the ever-increasing demand for digital healthcare and proper training programs, choosing an LMS that allows tailored training for medical professionals is vital. Equally as important is the need for LMS platforms to be compliant with state, local, and federal regulations. eLearning Industry carefully selected the Meridian LMS as a solution that encompasses these needs.

“We are truly honored and humbled to be recognized yet again by eLearning Industry,” states Meridian’s Chief Growth Officer, Sean Osborne. “The team continues to provide an LMS that can adapt to current and projected industry needs while simultaneously upskilling professionals. We look forward to forging ahead in our LMS capabilities in the healthcare and medical fields.”

Over the course of 25 years, Meridian has driven positive results and increased customer loyalty through its powerful LMS. Jam-packed with features such as mobile learning and personalization, The Meridian LMS is well-equipped to help professionals succeed in their respective fields and bridge any present skill gaps. With its expertise in blended learning, Meridian can cater to the learning and development needs of each organization based on what environment is best for them. With highly trained employees, organizations can see improved patient results and satisfaction.

Read more about the Meridian LMS’ healthcare, medical, and telemedicine capabilities here.

About Meridian Knowledge Solutions

Powering progress with compliance training, branded and blended learning environments, and eCommerce solutions, the Meridian Learning Management System (LMS) addresses complex learning challenges for customers such as Federal Emergency Management Agency (FEMA), Institute of Electrical and Electronics Engineers (IEEE), Commonwealth of Virginia, Johnson Controls, Abbott and Auto Club Group.

Our award-winning enterprise-level learning management platform offers our proprietary Learning Record Store (LRS), Career Explorer, and content authoring tools, and it natively integrates content provided by our partner OpenSesame. The Meridian LMS is available in the cloud, on-premise, or as private cloud. For more information, visit http://www.meridianks.com or follow @MeridianKS on Twitter.

Share article on social media or email:



Top Behavioral Health Organization Leverages Salesforce for Improved Contact Center Experience


DecisivEdge, a business consulting and technology firm, in partnership with Salesforce, has transformed the patient admission process at a top 5 U.S. behavioral health center. This patient-focused recovery center support model is driving value across the organization’s operation by reducing inbound call abandon rates, cutting time to admission, improving patient experiences and enhancing call center agent success.

The foundation for these improvements is a call center workflow that integrates and optimizes Salesforce actions. With task-based workflows that incorporate an intuitive user interface (UI) and user experience (UX), call center agents are able to capture information and match patient needs to the right facility quickly and clearly.

“Call center agents are on the front lines of patient care, yet too often their tools are disparate and disconnected,” says Karl Fischer, Managing Director CX Transformation at DecisivEdge. “With technology, analytics and a data-driven strategy, we are able to deliver a streamlined desktop workflow that enables these agent to drive a more effective, meaningful patient conversations.”

The new recovery center support model workflow moves the agent through stages from point of contact to admission, including an application to schedule patient pickups that integrates with the advisor’s case intake screens. Throughout the development of the call center solution, the DecisivEdge team focused on ensuring that the call center agent has the flexibility to transition quickly from one task to another while maintaining visibility to open areas, fall outs, and next steps to complete an admission.

Further, the solution includes an interface, facilitated by a Boomi cloud-based enterprise integration Platform as a Service (iPaaS), between EHR and Salesforce for a more intuitive patient admission process. Other tools include a Salesforce-integrated patient financial calculator and patient benefits history application.

To-date, the flexibility and intuitive workflow of the call center support model has demonstrated impressive results. The behavioral health center has reduced repeat call abandon rates by over 90%, improved conversion rates by nearly 40% and reduced time of admission by over 30%. One unanticipated benefit has been a more consistent and efficient agent training and on-boarding program. Agent training time has also been reduced by a whopping 80%. Also, from a business standpoint, the organization has seen a reduction in its operating budget by as much as 40%.

John Wilson, DecisivEdge’s Director of Salesforce Practice, and former Vice President of CRM at Recovery Centers of America where he was responsible for delivering Salesforce solutions to increase quality and end user efficiency, notes, “From a business perspective, behavioral health centers are necessarily focused on revenue per call, revenue per agent, cost per admission, etc., with the objective to get qualified candidates through to the agents and assessed as quickly as possible, and then into the facility to start treatment. To do that, we must eliminate the all-to-common scenario where call center agents jump between multiple systems on a single call. Our mission is to help organizations get the right call to the right agent the first time and to connect people to the help they need.”

DecisivEdge’s Salesforce consultants have extensive experience integrating and optimizing healthcare contact center solutions into the Salesforce CRM platform, increasing efficiency and productivity through digital transformation. By collaborating with a variety of partners including Five9, DecisivEdge has expertise with most major contact center platforms, enhancing Customer Experience (CX) and the UI/UX delivered to agents. DecisivEdge is a team of certified developers, administrators, and custom application builders.

Wilson concludes, “We help clients from various industries design, execute and implement a personalized Salesforce strategy. Your business challenges aren’t out of the box, your Salesforce shouldn’t be either.”

About Salesforce

Salesforce, the global CRM leader, empowers companies of every size and industry to digitally transform and create a 360° view of their customers. For more information about Salesforce (NYSE: CRM), visit: http://www.salesforce.com. Salesforce has headquarters in San Francisco, with offices in Europe and Asia, and trades on the New York Stock Exchange under the ticker symbol “CRM.”

About DecisivEdge

DecisivEdge is a global business consulting and technology services firm focused on creating a sustainable competitive edge through digital transformations. We help our clients elevate their operational capabilities and seize their market opportunity by leveraging and optimizing best-in-class technology solutions in conjunction with detailed analytics and data-driven operational strategies. We provide end-to-end services from the design and build of a fully integrated solution to the implementation, testing and optimization of that solution to assure effective results and a seamless user experience.

A deep knowledge of, and experience with Salesforce, call centers and multiple platforms prepares DecisivEdge to deal with complex projects, from custom features and time-saving process automations, to multi-platform integrations that improve data integrity and validity, to end-to-end implementation executed quickly and efficiently. DecisivEdge also provides training and support on any implementation for better user adoption, ongoing Salesforce maintenance and support, and continuous business strategy and improvement services. Visit us on the Salesforce App Exchange

DecisivEdge will be attending the Behavioural Health Business VALUE event March 16, 2023 in Washington, DC. VALUE is a full-day conference for industry executives focused on the future of value-based care in behavioral health. We will also be exhibiting at the The National Association of Addiction Treatment Providers (NAATP) National 2023 May 21-23 in Washington, DC.

Share article on social media or email: